网络荟萃分析表明,ω-3 多不饱和脂肪酸在预防临床高危人群向精神病转变方面具有卓越功效。

IF 4.5 2区 医学 Q1 CLINICAL NEUROLOGY
Chengfeng Chen, Yongyan Deng, Yuling Li, Meiting Zhang, Tong Yu, Kun Xie, Wuyou Bao, Peiying Li, Ling Sun, Tianhong Zhang, Yikang Zhu, Bin Zhang
{"title":"网络荟萃分析表明,ω-3 多不饱和脂肪酸在预防临床高危人群向精神病转变方面具有卓越功效。","authors":"Chengfeng Chen, Yongyan Deng, Yuling Li, Meiting Zhang, Tong Yu, Kun Xie, Wuyou Bao, Peiying Li, Ling Sun, Tianhong Zhang, Yikang Zhu, Bin Zhang","doi":"10.1093/ijnp/pyae014","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The efficacy of pharmacological and nutritional interventions in individuals at clinical high risk for psychosis (CHR-P) remains elusive. This study aims to investigate the efficacy of pharmacological and nutritional interventions in CHR-P and whether these interventions can enhance the efficacy of psychological treatments.</p><p><strong>Methods: </strong>We systematically reviewed data from 5 databases until July 24, 2021: PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, and WanFang Data. The primary outcome was the transition to psychosis. Network meta-analyses were conducted at 3 time points (6, 12, and ≥24 months) considering both pharmacological/nutritional interventions alone and its combination with psychotherapy.</p><p><strong>Results: </strong>Out of 11 417 identified references, 21 studies were included, comprising 1983 participants. CHR-P participants receiving omega-3 polyunsaturated fatty acids treatment were associated with a lower probability of transition compared with placebo/control at 6 months (odds ratio [OR] = 0.07, 95% confidence interval [CI] = .01 to .054), 12 months (OR = 0.14, 95% CI = .03 to .66), and ≥24 months (OR = 0.16, 95% CI = .05 to .54). Moreover, risperidone plus psychotherapy was associated with a lower likelihood of transition at 6 months compared with placebo/control plus psychotherapy, but this result was not sustained over longer durations.</p><p><strong>Conclusion: </strong>Omega-3 polyunsaturated fatty acids helped in preventing transitions to psychosis compared with controls.</p><p><strong>Prospero registration number: </strong>CRD42021256209.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949445/pdf/","citationCount":"0","resultStr":"{\"title\":\"Network Meta-Analysis Indicates Superior Effects of Omega-3 Polyunsaturated Fatty Acids in Preventing the Transition to Psychosis in Individuals at Clinical High-Risk.\",\"authors\":\"Chengfeng Chen, Yongyan Deng, Yuling Li, Meiting Zhang, Tong Yu, Kun Xie, Wuyou Bao, Peiying Li, Ling Sun, Tianhong Zhang, Yikang Zhu, Bin Zhang\",\"doi\":\"10.1093/ijnp/pyae014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The efficacy of pharmacological and nutritional interventions in individuals at clinical high risk for psychosis (CHR-P) remains elusive. This study aims to investigate the efficacy of pharmacological and nutritional interventions in CHR-P and whether these interventions can enhance the efficacy of psychological treatments.</p><p><strong>Methods: </strong>We systematically reviewed data from 5 databases until July 24, 2021: PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, and WanFang Data. The primary outcome was the transition to psychosis. Network meta-analyses were conducted at 3 time points (6, 12, and ≥24 months) considering both pharmacological/nutritional interventions alone and its combination with psychotherapy.</p><p><strong>Results: </strong>Out of 11 417 identified references, 21 studies were included, comprising 1983 participants. CHR-P participants receiving omega-3 polyunsaturated fatty acids treatment were associated with a lower probability of transition compared with placebo/control at 6 months (odds ratio [OR] = 0.07, 95% confidence interval [CI] = .01 to .054), 12 months (OR = 0.14, 95% CI = .03 to .66), and ≥24 months (OR = 0.16, 95% CI = .05 to .54). Moreover, risperidone plus psychotherapy was associated with a lower likelihood of transition at 6 months compared with placebo/control plus psychotherapy, but this result was not sustained over longer durations.</p><p><strong>Conclusion: </strong>Omega-3 polyunsaturated fatty acids helped in preventing transitions to psychosis compared with controls.</p><p><strong>Prospero registration number: </strong>CRD42021256209.</p>\",\"PeriodicalId\":14134,\"journal\":{\"name\":\"International Journal of Neuropsychopharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949445/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Neuropsychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ijnp/pyae014\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ijnp/pyae014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:药物和营养干预对临床高危精神病患者(CHR-P)的疗效仍然难以确定。本研究旨在探讨药物和营养干预对临床高危精神病患者的疗效,以及这些干预是否能提高心理治疗的疗效:我们系统地查阅了截至 2021 年 7 月 24 日的五个数据库的数据:PubMed、Web of Science、EMBASE、中国国家知识基础设施和万方数据。主要结果是向精神病的转变。在三个时间点(6个月、12个月和≥24个月)进行了网络荟萃分析,考虑了单独的药物/营养干预以及与心理治疗的结合:在已确定的11417篇参考文献中,纳入了21项研究,共有1983名参与者。与安慰剂/对照组相比,接受ω-3多不饱和脂肪酸治疗的CHR-P患者在6个月(OR为0.07,95% CI为0.01至0.054)、12个月(OR为0.14,95% CI为0.03至0.66)和≥24个月(OR为0.16,95% CI为0.05至0.54)时的转归概率较低。此外,利培酮加心理治疗与安慰剂/对照组加心理治疗相比,在6个月时转归的可能性较低,但这一结果在更长的时间内并不持续:结论:与对照组相比,欧米伽-3多元不饱和脂肪酸有助于防止患者转为精神病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Network Meta-Analysis Indicates Superior Effects of Omega-3 Polyunsaturated Fatty Acids in Preventing the Transition to Psychosis in Individuals at Clinical High-Risk.

Background: The efficacy of pharmacological and nutritional interventions in individuals at clinical high risk for psychosis (CHR-P) remains elusive. This study aims to investigate the efficacy of pharmacological and nutritional interventions in CHR-P and whether these interventions can enhance the efficacy of psychological treatments.

Methods: We systematically reviewed data from 5 databases until July 24, 2021: PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, and WanFang Data. The primary outcome was the transition to psychosis. Network meta-analyses were conducted at 3 time points (6, 12, and ≥24 months) considering both pharmacological/nutritional interventions alone and its combination with psychotherapy.

Results: Out of 11 417 identified references, 21 studies were included, comprising 1983 participants. CHR-P participants receiving omega-3 polyunsaturated fatty acids treatment were associated with a lower probability of transition compared with placebo/control at 6 months (odds ratio [OR] = 0.07, 95% confidence interval [CI] = .01 to .054), 12 months (OR = 0.14, 95% CI = .03 to .66), and ≥24 months (OR = 0.16, 95% CI = .05 to .54). Moreover, risperidone plus psychotherapy was associated with a lower likelihood of transition at 6 months compared with placebo/control plus psychotherapy, but this result was not sustained over longer durations.

Conclusion: Omega-3 polyunsaturated fatty acids helped in preventing transitions to psychosis compared with controls.

Prospero registration number: CRD42021256209.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.40
自引率
2.10%
发文量
230
审稿时长
4-8 weeks
期刊介绍: The central focus of the journal is on research that advances understanding of existing and new neuropsychopharmacological agents including their mode of action and clinical application or provides insights into the biological basis of psychiatric disorders and thereby advances their pharmacological treatment. Such research may derive from the full spectrum of biological and psychological fields of inquiry encompassing classical and novel techniques in neuropsychopharmacology as well as strategies such as neuroimaging, genetics, psychoneuroendocrinology and neuropsychology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信